Chymase: A multifunctional player in pulmonary hypertension associated with lung fibrosis

European Respiratory Journal

Volumn 46, Issue 4, 2015, Pages 1084-1094

  Kosanovic, Djuro ^a,b   Luitel, Himal ^a   Dahal, Bhola Kumar ^a,c   Cornitescu, Teodora ^a   Janssen, Wiebke ^a   Danser, A H Jan ^d   Garrelds, Ingrid M ^d   De Mey, Jo G R ^e,f   Fazzi, Gregorio ^f   Schiffers, Paul ^f   Iglarz, Marc ^g   Fischli, Walter ^a   Ghofrani, Hossein Ardeschir ^a   Weissmann, Norbert ^a   Grimminger, Friedrich ^a   Seeger, Werner ^a,h   Reiss, Irwin ^b   Schermuly, Ralph Theo ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g ACTELION PHARMACEUTICALS LTD   (Switzerland)

^h MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMASE; ENDOTHELIN 1; GELATINASE A; TRANSFORMING GROWTH FACTOR BETA1; BLEOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL ACTIVITY; CELL COUNT; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; HAMSTER; LUNG FIBROSIS; LUNG HEMODYNAMICS; MAST CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; VASOCONSTRICTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; HEART RIGHT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG; MESOCRICETUS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOIMMUNOASSAY; RANDOMIZATION;

ANIMALS; BLEOMYCIN; CHYMASES; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; IMMUNOHISTOCHEMISTRY; LUNG; MAST CELLS; MATRIX METALLOPROTEINASE 2; MESOCRICETUS; PULMONARY ARTERY; PULMONARY FIBROSIS; RADIOIMMUNOASSAY; RANDOM ALLOCATION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84943258374     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00018215     Document Type: Conference Paper

References (48)

1. Corte TJ, Wort SJ, Wells AU. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 7-19.
2. Dahal BK, Kosanovic D, Kaulen C, et al. Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir Res 2011; 12: 60.
3. Wygrecka M, Dahal BK, Kosanovic D, et al. Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: role of transmembrane SCF and the PAR-2/PKC-α/Raf-1/p44/42 signaling pathway. Am J Pathol 2013; 182: 2094-2108.
4. Krishnaswamy G, Kelley J, Johnson D, et al. The human mast cell: functions in physiology and disease. Front Biosci 2001; 6: D1109-D1127.
5. Kosanovic D, Dahal BK, Wygrecka M, et al. Mast cell chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis? Histol Histopathol 2013; 28: 691-699.
6. Tchougounova E, Lundequist A, Fajardo I, et al. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2005; 280: 9291-9296.
7. Kofford MW, Schwartz LB, Schechter NM, et al. Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J Biol Chem 1997; 272: 7127-7131.
8. Nagata N, Niwa Y, Nakaya Y. A novel 31-amino-acid-length endothelin, ET-1(1-31), can act as a biologically active peptide for vascular smooth muscle cells. Biochem Biophys Res Commun 2000; 275: 595-600.
9. Simard E, Jin D, Takai S, et al. Chymase-dependent conversion of Big endothelin-1 in the mouse in vivo. J Pharmacol Exp Ther 2009; 328: 540-548.
10. D'Orléans-Juste P, Houde M, Rae GA, et al. Endothelin-1 (1-31): from chymase-dependent synthesis to cardiovascular pathologies. Vascul Pharmacol 2008; 49: 51-62.
11. Mizutani H, Schechter N, Lazarus G, et al. Rapid and specific conversion of precursor interleukin 1β (IL-1β) to an active IL-1 species by human mast cell chymase. J Exp Med 1991; 174: 821-825.
12. Omoto Y, Tokime K, Yamanaka K, et al. Human mast cell chymase cleaves pro-IL-18 and generates a novel and biologically active IL-18 fragment. J Immunol 2006; 177: 8315-8319.
13. Miyazaki M, Takai S, Jin D, et al. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther 2006; 112: 668-676.
14. Doggrell SA, Wanstall JC. Vascular chymase: pathophysiological role and therapeutic potential of inhibition. Cardiovasc Res 2004; 61: 653-662.
15. Takai S, Jin D, Sakaguchi M, et al. A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl) 3-(2-ethoxy-benzyl)-4-oxo-azetidin e-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther 2003; 305: 17-23.
16. Tomimori Y, Muto T, Saito K, et al. Involvement of mast cell chymase in bleomycin-induced pulmonary fibrosis in mice. Eur J Pharmacol 2003; 478: 179-185.
17. Uhal BD, Li X, Piasecki CC, et al. Angiotensin signalling in pulmonary fibrosis. Int J Biochem Cell Biol 2012; 44: 465-468.
18. Ogo T, Chowdhury HM, Yang J, et al. Inhibition of overactive transforming growth factor-beta signaling by prostacyclin analogs in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2013; 48: 733-741.
19. Uguccioni M, Pulsatelli L, Grigolo B, et al. Endothelin-1 in idiopathic pulmonary fibrosis. J Clin Pathol 1995; 48: 330-334.
20. Kosanovic D, Kojonazarov B, Luitel H, et al. Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension. Respir Res 2011; 12: 87.
21. Fonseca C, Abraham D, Renzoni EA. Endothelin in pulmonary fibrosis. Am J Respir Cell Mol Biol 2011; 44: 1-10.
22. Chelladurai P, Seeger W, Pullamsetti SS. Matrix metalloproteinases and their inhibitors in pulmonary hypertension. Eur Respir J 2012; 40: 766-782.
23. Dancer RC, Wood AM, Thickett DR. Metalloproteinases in idiopathic pulmonary fibrosis. Eur Respir J 2011; 38: 1461-1467.
24. Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-β signaling in fibrosis. Growth Factors 2011; 29: 196-202.
25. Lepparanta O, Sens C, Salmenkivi K, et al. Regulation of TGF-β storage and activation in the human idiopathic pulmonary fibrosis lung. Cell Tissue Res 2012; 348: 491-503.
26. Schermuly RT, Ghofrani HA, Wilkins MR, et al. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011; 8: 443-455.
27. Kishi K, Jin D, Takai S, et al. Role of chymase-dependent angiotensin II formation in monocrotaline-induced pulmonary hypertensive rats. Pediatr Res 2006; 60: 77-82.
28. Farha S, Sharp J, Asosingh K, et al. Mast cell number, phenotype, and function in human pulmonary arterial hypertension. Pulm Circ 2012; 2: 220-228.
29. Mitani Y, Ueda M, Maruyama K, et al. Mast cell chymase in pulmonary hypertension. Thorax 1999; 54: 88-90.
30. Kosanovic D, Dahal BK, Peters DM, et al. Histological characterization of mast cell chymase in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Pulm Circ 2014; 4: 128-136.
31. Kunori Y, Muroga Y, Iidaka M, et al. Species differences in angiotensin II generation and degradation by mast cell chymases. J Recept Signal Transduct Res 2005; 25: 35-44.
32. Dahal BK, Kosanovic D, Pamarthi PK, et al. Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. Eur Respir J 2010; 36: 808-818.
33. Udalov S, Dumitrascu R, Pullamsetti SS, et al. Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. BMC Pulm Med 2010; 10: 26.
34. Tschanz SA, Burri PH, Weibel ER. A simple tool for stereological assessment of digital images: the STEPanizer. J Microsc 2011; 243: 47-59.
35. Sakaguchi M, Takai S, Jin D, et al. A specific chymase inhibitor, NK3201, suppresses bleomycin-induced pulmonary fibrosis in hamsters. Eur J Pharmacol 2004; 493: 173-176.
36. Takato H, Yasui M, Ichikawa Y, et al. The specific chymase inhibitor TY-51469 suppresses the accumulation of neutrophils in the lung and reduces silica-induced pulmonary fibrosis in mice. Exp Lung Res 2011; 37: 101-108.
37. Reber LL, Daubeuf F, Pejler G, et al. Mast cells contribute to bleomycin-induced lung inflammation and injury in mice through a chymase/mast cell protease 4-dependent mechanism. J Immunol 2014; 192: 1847-1854.
38. Bartelds B, van Loon RL, Mohaupt S, et al. Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension. Chest 2012; 141: 651-660.
39. Wang T, Han SX, Zhang SF, et al. Role of chymase in cigarette smoke-induced pulmonary artery remodeling and pulmonary hypertension in hamsters. Respir Res 2010; 11: 36.
40. Li J, Lu H, Plante E, et al. Stem cell factor is responsible for the rapid response in mature mast cell density in the acutely stressed heart. J Mol Cell Cardiol 2012; 53: 469-474.
41. Gilfillan AM, Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol Rev 2009; 228: 149-169.
42. Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res 2006; 34: 97-115.
43. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961.
44. Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434-2440.
45. Maurer M, Wedemeyer J, Metz M, et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 2004; 432: 512-516.
46. Takai S, Jin D, Muramatsu M, et al. Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis. Eur J Pharmacol 2004; 501: 1-8.
47. Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol 1991; 44: 1003-1006.
48. Hamada H, Terai M, Kimura H, et al. Increased expression of mast cell chymase in the lungs of patients with congenital heart disease associated with early pulmonary vascular disease. Am J Respir Crit Care Med 1999; 160: 1303-1308.